Voya Investment Management LLC grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 842.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 90,011 shares of the medical research company's stock after acquiring an additional 80,456 shares during the period. Voya Investment Management LLC owned 0.19% of Charles River Laboratories International worth $26,554,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in the business. Bank of America Corp DE boosted its position in shares of Charles River Laboratories International by 5.0% during the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company's stock valued at $195,792,000 after purchasing an additional 54,500 shares in the last quarter. Aberdeen Group plc grew its stake in Charles River Laboratories International by 483.6% during the third quarter. Aberdeen Group plc now owns 792,576 shares of the medical research company's stock worth $233,818,000 after purchasing an additional 656,777 shares during the period. Amundi grew its stake in Charles River Laboratories International by 175.2% during the first quarter. Amundi now owns 773,315 shares of the medical research company's stock worth $133,397,000 after purchasing an additional 492,301 shares during the period. Russell Investments Group Ltd. increased its holdings in Charles River Laboratories International by 457.3% in the third quarter. Russell Investments Group Ltd. now owns 436,055 shares of the medical research company's stock worth $128,641,000 after purchasing an additional 357,817 shares in the last quarter. Finally, Danske Bank A S increased its holdings in Charles River Laboratories International by 308,855.0% in the third quarter. Danske Bank A S now owns 308,955 shares of the medical research company's stock worth $91,145,000 after purchasing an additional 308,855 shares in the last quarter. 98.91% of the stock is owned by institutional investors.
Charles River Laboratories International Stock Down 4.2%
Shares of NYSE CRL opened at $314.29 on Friday. The stock has a market capitalization of $15.06 billion, a P/E ratio of 345.37, a P/E/G ratio of 3.03 and a beta of 1.36. The company has a 50-day moving average price of $316.09 and a 200-day moving average price of $231.19. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $379.63. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.41 and a quick ratio of 1.12.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, topping analysts' consensus estimates of $2.97 by $0.12. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The company had revenue of $982.73 million for the quarter, compared to analyst estimates of $960.36 million. During the same quarter in the prior year, the business posted $2.43 EPS. The firm's revenue was down 2.2% compared to the same quarter last year. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.45 EPS for the current fiscal year.
Insider Transactions at Charles River Laboratories International
In other news, EVP Shannon Parisotto sold 2,156 shares of the stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the sale, the executive vice president directly owned 4,807 shares of the company's stock, valued at $1,655,578.87. This represents a 30.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James C. Foster sold 33,561 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares of the company's stock, valued at approximately $9,478,800. This trade represents a 51.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 60,740 shares of company stock valued at $19,528,128 in the last quarter. Company insiders own 1.30% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the company. Royal Bank Of Canada boosted their price target on Charles River Laboratories International from $322.00 to $352.00 and gave the company an "outperform" rating in a research note on Thursday, November 5th. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a research report on Monday, August 10th. Barclays lifted their price objective on shares of Charles River Laboratories International from $330.00 to $375.00 and gave the company an "overweight" rating in a research note on Thursday, November 5th. Zacks Research downgraded shares of Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a research report on Monday, November 2nd. Finally, Argus set a $330.00 target price on shares of Charles River Laboratories International in a research note on Thursday, September 17th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $311.67.
Get Our Latest Stock Analysis on CRL
About Charles River Laboratories International
(
Free Report)
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company's offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Charles River Laboratories International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.
While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.